1. Home >
  2. M&A >
  3. Bankruptcy >
  4. United States >
  5. Massachusetts >
  6. CLS Therapeutics Exits VBI Vaccines

Investment Summary

CLS Therapeutics Exits VBI Vaccines

On July 30, 2024, invested in life science company VBI Vaccines from CLS Therapeutics

Investment Highlights
  • This is transaction in the Life Science sector.
  • This is transaction in the United States.
  • This is transaction in Massachusetts.

Investment Summary
Date 2024-07-30
Target VBI Vaccines
Sector Life Science
Sellers(s) CLS Therapeutics
Deal Type Bankruptcy

Target

VBI Vaccines

Cambridge, Massachusetts, United States
VBI Vaccines is a biopharmaceutical company focused on the development and commercialization of novel and improved therapies for the prevention and treatment of hepatitis B and Graft-vs-Host Disease (GVHD) using our proprietary recombinant protein expertise. VBI Vaccines was founded in 2005 and is based in Cambridge, Massachusetts.

Search 214,239 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Seller(S) 1

SELLER

CLS Therapeutics

Guernsey, United Kingdom
Category Company
Sector Life Science
DESCRIPTION

CLS Therapeutics Ltd. is a pharmaceutical company.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Bankruptcy M&A Deals 1 of 1
State: Massachusetts M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2024 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-07-10 VBI Vaccines

Cambridge, Massachusetts, United States

VBI Vaccines is a biopharmaceutical company focused on the development and commercialization of novel and improved therapies for the prevention and treatment of hepatitis B and Graft-vs-Host Disease (GVHD) using our proprietary recombinant protein expertise. VBI Vaccines was founded in 2005 and is based in Cambridge, Massachusetts.

Buy -
Mergr

Solution for

Product

Company

Legal